P305: Low ALT is more Common in Patients with IBD than Healthy Controls and is Associated with Active DiseaseECCO'22Year: 2022
Authors: Shafrir, A.(1,2,3);Katz, L.(1,2);Zinger, A.(1,2);Safadi, R.(1,2);Kaliski, I.(1,2);
(1)Hadassah Medical Center, Department of Gastroenterology and Hepatology, Jerusalem, Israel;(2)Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel;(3)Meuhedet Health Maintenace Organization, Jerusalem District, Tel Aviv, Israel;
P306: Efficacy and tolerance of sodium picosulfate preparation in bowel Magnetic Resonance Imaging in Crohn’s diseaseECCO'22Year: 2022
Authors: Juif, L.(1);Calame, P.(1);Chausset, C.(1);Koch, S.(1);Briot, C.(2);De Billy, M.(1);Vuitton, L.(1);
(1)chru jean minjoz, Doubs, Besancon, France;(2)Ch Haute saone, Doubs, Besancon, France;
P307: The effect of COVID-19 infection and vaccination in patients with Inflammatory Bowel Disease and Irritable Bowel Syndrome.ECCO'22Year: 2022
Authors: Sciberras, N.(1);Pisani, A.(2);Vassallo, C.(1);Zahra Bianco, E.(2);Ellul, P.(2);
(1)Mater Dei Hospital, Medicine, Msida, Malta;(2)Mater Dei Hospital, Gastroenterology, Msida, Malta;
P308: Quadruple oral antibiotic treatment in refractory Paediatric Inflammatory Bowel Disease – incidence and analysis of responders from a 10 year cohort.ECCO'22Year: 2022
Authors: Meredith, J.J.(1,2);Armstrong, K.(1);Russell, R.K.(1,2);Henderson, P.(1,2);Wilson, D.C.(1,2);
(1)Royal Hospital for Children and Young People, Department of Paediatric Gastroenterology and Nutrition, Edinburgh, United Kingdom;(2)University of Edinburgh, Child Life and Health- College of Medicine and Veterinary Medicine, Edinburgh, United Kingdom;
P309: Withdrawal of thiopurines in Inflammatory Bowel Disease patients in stable remission: a prospective, multicentre cohort studyECCO'22Year: 2022
Authors: Savelkoul, E.(1);Mahmoud, R.(2);De Jong, D.(1);Van Dop, W.(1);Römkens, T.(3);Nissen, L.(3);Mahmmod, N.(4);Van Boeckel, P.(4);Lutgens, M.(5);Mares, W.(6);Epping, L.(7);Minderhoud, I.(8);Jansen, J.(9);Gisbertz, I.(10);Boekema, P.(11);De Koning, D.(12);Horjus, C.(13);Jharap, B.(14);Oldenburg, B.(2);Hoentjen, F.(15);
(1)Radboud University Medical Centre, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(2)University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(3)Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, 's-Hertogenbosch, The Netherlands;(4)St. Antonius Hospital, Department of Gastroenterology and Hepatology, Nieuwegein, The Netherlands;(5)Elisabeth-TweeSteden Hospital, Department of Gastroenterology and Hepatology, Tilburg, The Netherlands;(6)Gelderse Vallei Hospital, Department of Gastroenterology and Hepatology, Ede, The Netherlands;(7)Pantein Hospital, Department of Gastroenterology and Hepatology, Boxmeer, The Netherlands;(8)Tergooi Medical Centre, Department of Gastroenterology and Hepatology, Hilversum, The Netherlands;(9)Onze Lieve Vrouwe Gasthuis OLVG, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(10)Bernhoven Hospital, Department of Gastroenterology and Hepatology, Uden, The Netherlands;(11)Máxima Medical Centre, Department of Gastroenterology and Hepatology, Veldhoven, The Netherlands;(12)Gelre Hospital, Department of Gastroenterology and Hepatology, Apeldoorn, The Netherlands;(13)Rijnstate Hospital, Department of Gastroenterology and Hepatology, Arnhem, The Netherlands;(14)Meander Medical Centre, Department of Gastroenterology and Hepatology, Amersfoort, The Netherlands;(15)University of Alberta, Division of Gastroenterology- Department of Medicine, Edmonton, Canada;The AWARE study group and the Dutch Initiative on Crohn’s and Colitis
P310: Atopic dermatitis is associated with the clinical course of Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: Kim, K.W.(1);Ha, H.(2);Jun, Y.(1);Lee, H.J.(1);Yoon, H.(3);Kang, H.W.(4);Im, J.P.(1);Kim, J.S.(1);Koh, S.J.(1);
(1)Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, Korea- Republic Of;(2)Seoul National University College of Medicine, Medical school, Seoul, Korea- Republic Of;(3)Seoul National University Bundang Hospital, Department of Internal Medicine, Seongnam-si, Korea- Republic Of;(4)Seoul National University Boramae Medical Center, Department of Internal Medicine, Seoul, Korea- Republic Of;
P311: Depression and anxiety are associated with poor clinical outcomes in Inflammatory Bowel Disease : A Nationwide Population-Based Study in South KoreaECCO'22Year: 2022
Authors: Kim, S.(1);Seungwoo, L.(2);Kyungdo, H.(2);Hyun Jung , L.(1);Jong Pil , I.(1);Joo Sung, K.(1);
(1)Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, Korea- Republic Of;(2)Soongsil University, Department of Statistics and Actuarial Science, Seoul, Korea- Republic Of;
P312: Combination corticosteroids with 5-aminosalicylic acid versus corticosteroids alone in the treatment of hospitalized patients with acute severe ulcerative colitis: A multi-center randomized controlled trialECCO'22Year: 2022
Authors: Ben-Horin, S.(1,2);Har-Noy, O.(1);Katsanos, K.H.(3);Xavier, R.(4);Chen, M.H.(2);Gao, X.(5);Schwartz, D.(6);Cheon, J.H.(7);Cesarini, M.(8);Bojic, D.(9);Protic, M.(9);Theodoropoulou, A.(10);Abu-Kaf, H.(6);Engel, T.(1);Tang, J.(5);Veyrard, P.(4);Lin, X.(2);Mao, R.(2);Christodoulou, D.(3);Karmiris, K.(10);Knezevic-Ivanovski, T.(9);
(1)Tel-HaShomer Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;(2)First affiliated Hospital of the Sun Yatsen University, Gastroenterology, Guangzhou, China;(3)University of Ioannina, Gastroenterology, Ioannina, Greece;(4)University-Hospital of Saint-Etienne, Gastroenterology, Saint-Etienne, France;(5)Sixth affiliated Hospital of the Sun Yatsen University, Gastroenterology, Guangzhou, China;(6)Soroka University Medical Center, Gastroenterology, Beer-Sheva, Israel;(7)Yonsei University College of Medicine, Gastroenterology, Seoul, Korea- Republic Of;(8)@Sapienza@- University of Rome, Gastroenterology, Rome, Italy;(9)University Hospital Zvezdara, Gastroenterology, Belgrade, Serbia;(10)Venizeleio General Hospital, Gastroenterology, Heraklion- Crete, Greece;ComboMesa
P313: Within 6 months from COVID-19 BNT162b2 vaccine patients with Inflammatory Bowel Diseases treated with Anti-TNFα have significantly lower serologic responsesECCO'22Year: 2022
Authors: Rabinowitz, K.M.(1,2);Navon, M.(3);Edelman-Klapper, H.(1,4);Zittan, E.(5,6);Bar-Gil Shitrit, A.(7,8);Goren, I.(1,4);Avni-Biron, I.(1,4);Ollech, J.E.(1,4);Lichtenstein, L.(9);Banai-Eran, H.(1,4);Yanai, H.(1,4);Snir, Y.(1,4); Pauker, M.H.(1);Friedenberg, A.(1);Levy-Barda, A.(10);Segal, A.(11);Broitman, Y.(1,4);Maoz, E.(12);Ovadia, B.(13);Aharoni Golan, M.(1);Shachar, E.(4,14);Ben-Horin, S.(4,14);Perets, T.T.(15,16);Ben Zvi, H.(17);Eliakim, R.(4,14);Barkan, R.(1);Goren, S.(18);Krugliak, N.(3);Werbner, M.(19);Alter, J.(20);Dessau, M.(20);Gal-Tanamy, M.(19);Cohen, D.(18);Freund, N.T.(3);Dotan, I.(1,4);
(1)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(2)Tel Aviv University, Felsenstein Medical Research Center, Tel Aviv, Israel;(3)Tel Aviv University, Department of Clinical Microbiology and immunology, Tel Aviv, Israel;(4)Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel;(5)Emek Medical Center, Department of Gastroenterology, Afula, Israel;(6)Technion-Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa, Israel;(7)Shaare Zedek Medical Center, Digestive diseases institute, Jerusalem, Israel;(8)Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel;(9)Clalit Health Services, Gastroenterology, Petah Tikva, Israel;(10)Rabin Medical Center, Biobank- Department of Pathology, Petah Tikva, Israel;(11)Soroka University Medical Center, The Institute of Gastroenterology and Hepatology, Beer-Sheva, Israel;(12)Clalit Health Services, Gastroenterology, Tel Aviv, Israel;(13)Hillel Yaffe Medical Center, Department of Gastroenterology and Hepatology, Hadera, Israel;(14)Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;(15)Rabin Medical Center, Gastroenterology Laboratory- Division of Gastroenterology, Petah Tikva, Israel;(16)Ariel University, Adelson School of Medicine, Ariel, Israel;(17)Rabin Medical Center, Microbiology lab, Petah Tikva, Israel;(18)Tel Aviv University, School of Public Health- Sackler Faculty of Medicine, Tel Aviv, Israel;(19)Bar-Ilan University, Molecular Virology Lab- The Azrieli Faculty of Medicine, Safed, Israel;(20)Bar-Ilan University, The Laboratory of Structural Biology of Infectious Diseases- The Azrieli Faculty of Medicine, Safed, Israel;REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]
P314: Elderly onset is associated with low efficacy of anti-TNF treatment in Bio-naïve IBD patients: A multicenter cohort study by the Osaka Gut ForumECCO'22Year: 2022
Authors: Amano, T.(1);Shinzaki, S.(1);Asakura, A.(1);Tashiro, T.(1);Otake, Y.(1);Tani, M.(1);Yoshihara, T.(1);Inoue, T.(1);Takehara, T.(1);
(1)Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Osaka, Japan;the Osaka Gut Forum
P315: High symptom burden and impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a global burden of illness studyECCO'22Year: 2022
Authors: Karki, C.(1);Sharpe, E.(2);Hantsbarger, G.(3);Lee, K.(4);Perovic, M.(5);Raven, L.(6);Sajak-Szczerba, M.(7);Silber, A.(2);Yoon, A.(8);Tozer, P.(9);
(1)Takeda Pharmaceuticals USA- Inc., Global Evidence and Outcomes, Cambridge MA, United States;(2)Trinity Partners- LLC, Heath Economics & Outcomes Research, Waltham- MA, United States;(3)Takeda Pharmaceuticals USA Inc., Safety and Health Value Statistics, Cambridge- MA, United States;(4)Crohn's & Colitis Canada, Research & Patient Programs, Toronto, Canada;(5)European Federation of Crohn’s and Ulcerative Colitis Associations, European Federation of Crohn’s and Ulcerative Colitis Associations, Brussels, Belgium;(6)Crohn's & Colitis Australia, n/a, Camberwell, Australia;(7)European Federation of Crohn’s and Ulcerative Colitis Associations, n/a, Brussels, Belgium;(8)Takeda Pharmaceuticals, Gastroenterology- Japan Medical Office, Tokyo, Japan;(9)St Mark’s Hospital and Academic Institute, Fistula Research Unit, London, United Kingdom;
P316: Ozanimod is an efficacious oral therapy after 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True NorthECCO'22Year: 2022
Authors: Sands, B.E.(1);Dignass, A.(2);Irving, P.(3);Chiorean, M.(4);Long, M.(5);Eren, D.(6);Ahmad, H.A.(6);Osterman, M.T.(6);Petersen, A.(6);Elegbe, A.(6);Ritter, T.(7);Danese, S.(8);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(2)Goethe University, Gastroenterology, Frankfurt, Germany;(3)Guy’s and St Thomas’ NHS Foundation Trust, Gastroenterology, London, United Kingdom;(4)Swedish Medical Center, Gastroenterology, Seattle, United States;(5)UNC Chapel Hill, Gastroenterology, Chapel Hill, United States;(6)Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States;(7)GI Alliance, Gastroenterology, Southlake, United States;(8)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Tbc, Milan, Italy;
P317: Ustekinumab Trough Concentrations Associated with Biochemical Outcomes in Patients with Crohn’s DiseaseECCO'22Year: 2022
Authors: Straatmijer , T.(1);Biemans , V.B.C.(1);Moes , D.J.A.R.(2);Hoentjen , F.(7);ter Heine , R.(4);Maljaars , P.W.J.(5);Theeuwen , R.(5);Pierik , M.(6);Duijvestein , M.(3);van der Meulen , A.E.(5);
(1)Initiative on Crohn and Colitis, Gastroenterology, Amsterdam / Leiden, The Netherlands;(2)Leiden University Medical Center, Clinical Pharmacy and Toxicology, Leiden, The Netherlands;(3)Radboud University Medical Center, Gastroenterology, Nijmegen, The Netherlands;(4)Radboud University Medical Center, Pharmacology and Toxicology, Nijmegen, The Netherlands;(5)Leiden University Medical Center, Gastroenterology, Leiden, The Netherlands;(6)Maastricht University Medical Center, Gastroenterology, Maastricht, The Netherlands;(7)University of Alberta, Division of Gastroenterology, Edmonton, Canada;Dutch Initiative on Crohn and Colitis
P318: Safety of Biological Therapies in Elderly IBD: a Systematic Review and Meta-analysisECCO'22Year: 2022
Authors: Drügg Hahn, G.(1);Golovics, P.(1);Wetwittayakhlang, P.(1);Santa Maria, D.(2);Britto, U.(2);Wild, G.(1);Afif, W.(1);Bessissow, T.(1);Bitton, A.(1);LakatosPhD, P.L.(1);
(1)Mcgill University Health Center, IBD Centre, Montréal, Canada;(2)Universidade Federal do Rio Grande do Sul, Departamento de Estatística, Porto Alegre, Brazil;
P319: Incorporating HLADQA1*05 in pre-biologic screening in IBD patients initiating biologic therapiesECCO'22Year: 2022
Authors: Aleman Gonzalez, H.(1);Ramachandran, S.(1);Whitehead, E.(1);Pattinson, A.(1);Stamp, K.(1);Turnbull, J.(1);Myers, S.(1);Talbot, A.(1);Sebastian, S.(1);
(1)Hull University Teaching Hospitals, Inflammatory Bowel Disease, Kingston Upon Hull, United Kingdom;
P320: 6-Thioguanine nucleotide levels are associated with trough levels of infliximab and adalimumab in Inflammatory Bowel Disease patients on combination therapy: A retrospective multicentre studyECCO'22Year: 2022
Authors: Yu, N.(1);Tassone, D.(1);Lee, T.(1);Phan, S.(2);Wu, D.M.(2);Tjahyadi, J.(3);Dutt, K.(3);Liou, H.(4);Wang, L.(5);Zhang, J.(6);Basnayake, C.(1,7);Wright, E.(1,7);Lust, M.(1);Niewiadomski, O.(1);Kamm, M.A.(1,7);Connell, W.(1);Thompson, A.(1,7);Hilmi, I.(8);Affendi Raja Ali, R.(9);Wei, S.C.(4);De Cruz, P.(2,7);van Langenberg, D.(3,10);Moore, G.T.(5,10);Friedman, A.B.(6);Ding, N.S.(1,7);
(1)St Vincent's Hospital Melbourne, Gastroenterology, Melbourne, Australia;(2)Austin Health, Gastroenterology, Melbourne, Australia;(3)Eastern Health, Gastroenterology, Melbourne, Australia;(4)National Taiwan University Hospital, Internal Medicine, Taipei, Taiwan;(5)Monash Health, Gastroenterology, Melbourne, Australia;(6)Alfred Health and Monash University, Gastroenterology, Melbourne, Australia;(7)University of Melbourne, Medicine, Melbourne, Australia;(8)University of Malaya Medical Centre, Medicine, Kuala Lumpur, Malaysia;(9)Universiti Kebangsaan Malaysia, Medicine, Kuala Lumpur, Malaysia;(10)Monash University, Medicine, Melbourne, Australia;COMBAT
P321: Mucosal Healing and Clinical remission after Treatment with Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA study): final results from a prospective, open-label, single-arm studyECCO'22Year: 2022
Authors: Wetwittayakhlang, P.(1);Golovics , P.(1);Hahn, G.(1);Bessissow, T.(1); Afif, W.(1);Wild, G.(1);Bitton, A.(1);LakatosPhD, P.L.(1);
(1)Mcgill University Health Center, IBD Centre, Montréal, Canada;IBD centre McGill University Health Centre
P322: Effectiveness of Tumor Necrosis Factor-alpha inhibitors and Thiopurines combination therapy according to 6-thioguanine nucleotides plasma levels: A Systematic Review.ECCO'22Year: 2022
Authors: Céspedes Martínez, E.(1);Robles, V.(1);Miarons, M.(2);Herrera-De Guise, C.(1);Mayorga-Ayala, L.(1);Perez, Z.(1);Oller, E.(1);Casellas, F.(1);Borruel, N.(1);
(1)Hospital Vall d'Hebron, Crohn's and colitis Attention Unit. Digestive System Research Unit., Barcelona, Spain;(2)Hospital Vall d'Hebron, Pharmacy Deparment- Hospital Vall d'Hebron Universitari Campus, Barcelona, Spain;
P323: The Crohn's Disease Exclusion Diet (CDED) for pouch inflammation: an interventional pilot studyECCO'22Year: 2022
Authors: Fliss Isakov, N.(1);Kornblum, J.(1);Zemel, M.(2);Hirsch, A.(1);Maharshak, N.(1);
(1)Tel Aviv Sourasky Medical Center, Department of Gastroenterology and Liver Diseases- Sackler Faculty of Medicine, Tel Aviv, Israel;(2)Tel Aviv Sourasky Medical Center, Surgery division, Tel Aviv, Israel;
P324: Tacrolimus for induction of remission in refractory ulcerative colitis: a Cochrane systematic reviewECCO'22Year: 2022
Authors: Gordon, M.(1);Sinopoulou, V.(1);Pana, M.(2);Moran, G.(2);
(1)UCLan, School of Medicine, Preston, United Kingdom;(2)University of Nottingham, Faculty of Medicine & Health Sciences, Nottingham, United Kingdom;
